Larimar Therapeutics (LRMR) Common Equity (2013 - 2025)

Larimar Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $78.1 million for Q4 2025.

• Quarterly Common Equity fell 54.55% year-over-year to $78.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $78.1 million (down 54.55% YoY) and the FY2025 annual result came in at $78.1 million, down 54.55% from the prior year.
• Common Equity was $78.1 million for Q4 2025 at Larimar Therapeutics, down from $139.0 million in the prior quarter.
• Across five years, Common Equity topped out at $230.8 million in Q1 2024 and bottomed at $50.1 million in Q2 2022.
• A 5-year average of $114.7 million and a median of $103.1 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 3392.2% — and 2025, when it slumped 54.55%.
• Larimar Therapeutics' Common Equity stood at $64.4 million in 2021, then surged by 72.17% to $110.9 million in 2022, then declined by 26.31% to $81.7 million in 2023, then surged by 110.24% to $171.8 million in 2024, then slumped by 54.55% to $78.1 million in 2025.
• Business Quant data shows LRMR's Common Equity at $78.1 million in Q4 2025, $139.0 million in Q3 2025, and $119.9 million in Q2 2025.